The rise of tamoxifen: temporal and geographical trends of tamoxifen use in Ontario
Palda VA, Goel V, Sawka CA. Breast Cancer Res Treat. 1997; 43(1):33-41.
Publications
Physicians’ opinions about decision aids for patients considering systemic adjuvant therapy for axillary-node negative breast cancer
O'Connor AM, Llewellyn-Thomas HA, Sawka C, Pinfold SP, To T, Harrison DE. Patient Educ Couns. 1997; 30(2):143-53.
Patterns of initial management of node-negative breast cancer in two Canadian provinces
Goel V, Olivotto I, Hislop TG, Sawka C, Coldman A, Holowaty EJ. CMAJ. 1997; 156(1):25-35.
Compliance with practice guidelines for node-negative breast cancer
Olivotto IA, Coldman AJ, Hislop TG, Trevisan CH, Kula J, Goel V, Sawka C. J Clin Oncol. 1997; 15(1):216-22.
The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer
Sawka C, Olivotto I, Coldman A, Goel V, Holowaty E, Hislop TG. Br J Cancer. 1997; 75(10):1534-42.
The context of measuring disability: does it matter whether capability or performance is measured?
Young NL, Williams JI, Yoshida KK, Bombardier C, Wright JG. J Clin Epidemiol. 1996; 49(10):1097-101
Using an alternative data source to examine randomization in the Canadian National Breast Screening Study
Cohen MM, Kaufert PA, MacWilliam L, Tate RB. Clin Epidemiol. 1996; 49(9):1039-44.
A cohort study on childhood asthma admissions and readmissions
To T, Dick P, Feldman W, Hernandez R. Pediatrics. 1996; 98(2):191-5.
Distribution of prescription drug exposures in the elderly: description and implications
Anderson G, Kerluke K. J Clin Epidemiol. 1996; 49(8):929-35.
Utilization of healthcare services by immigrants and other ethnic/cultural groups in Ontario
Wen SW, Goel V, Williams JI. Ethn Health. 1996; 1(1):99-109.